Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fesoterodine for Urgency in Parkinson's Disease
NCT02385500Phase 4Terminated
- Sponsor
- Jewish General Hospital
- Start
- Sep 2016
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in overactive bladder (OAB) comparing Fesoterodine First with Placebo First (2 arms). Primary endpoint: Urgency episodes at 20 weeks. Started Sep 2016; status: terminated.
02
Drugs
fesoterodine
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT02385500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02385500.